Consolidated Statements of Changes in Mezzanine Equity and Stockholders’ Deficit - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Series A Convertible Preferred Stock	Series B Convertible Preferred Stock	Redeemable Common Stock
Beginning balance (in shares) at Dec. 31, 2022					0	0	0
Beginning balance at Dec. 31, 2022					$ 0	$ 0	$ 0
Mezzanine Equity
Issuance of convertible preferred stock (in shares)					30,000
Issuance of convertible preferred stock					$ 3,867
Preferred stock issuance costs					(253)
Accretion					$ 4,591
Conversion of preferred stock (in shares)					(1,372)
Conversion of preferred stock					$ (350)
Ending balance (in shares) at Dec. 31, 2023					28,628	0	0
Ending balance at Dec. 31, 2023	$ 7,855				$ 7,855	$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2022		8,242,009
Beginning balance at Dec. 31, 2022	(10,635)	$ 1	$ 212,122	$ (222,758)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion on convertible preferred stock	(4,591)		(4,591)
Conversion of preferred stock (in shares)		200,000
Conversion of preferred stock	350		350
Issuance of warrants	43		43
Issuance of common stock for restricted stock units vesting (in shares)		294,119
Issuance of common stock for employee stock purchase plan (in shares)		43,274
Issuance of common stock for employee stock purchase plan	$ 215		215
Issuance of common stock upon exercise of stock options (in shares)	18,054	18,054
Issuance of common stock upon exercise of stock options	$ 55		55
Stock-based compensation	9,933		9,933
Net loss	(32,901)			(32,901)
Ending balance (in shares) at Dec. 31, 2023		8,797,456
Ending balance at Dec. 31, 2023	$ (37,531)	$ 1	218,127	(255,659)
Mezzanine Equity
Issuance of convertible preferred stock (in shares)						9,250
Issuance of convertible preferred stock						$ 2,394	4,308
Preferred stock issuance costs						(102)
Accretion					$ 3,765	$ 1,160	$ 26
Conversion of preferred stock (in shares)	(17,149)
Conversion of preferred stock	$ (6,469)
Issuance of redeemable common stock (in shares)							750,000
Ending balance (in shares) at Dec. 31, 2024					11,479	9,250	750,000
Ending balance at Dec. 31, 2024	12,937				$ 5,151	$ 3,452	$ 4,334
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accretion on convertible preferred stock	(4,926)		(4,926)
Accretion on redeemable common stock	(25)		(25)
Conversion of preferred stock (in shares)		2,499,848
Conversion of preferred stock	6,469		6,469
Issuance of common stock related to offering (in shares)		3,135,136
Issuance of common stock related to offering (Note 9)	11,601	$ 1	11,600
Common stock issuance costs	(2,266)		(2,266)
Issuance of warrants	382		382
RSU to RSA conversion (in shares)		387,309
Issuance of common stock for restricted stock units vesting (in shares)		812,746
Issuance of common stock for employee stock purchase plan (in shares)		59,325
Issuance of common stock for employee stock purchase plan	$ 221		221
Issuance of common stock upon exercise of stock options (in shares)	33,963	33,963
Issuance of common stock upon exercise of stock options	$ 143		143
Stock-based compensation	8,717		8,717
Net loss	(12,536)			(12,536)
Ending balance (in shares) at Dec. 31, 2024		15,725,783
Ending balance at Dec. 31, 2024	$ (29,751)	$ 2	$ 238,442	$ (268,195)